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Abstract
Background: The prevalence of chronic hepatitis C virus (HCV) infection in the Italian correctional population is
estimated to be around 38%. In this setting HCV infection treatment is controversial because of several factors such
as active drug substance abuse, psychiatric illness, length of treatment, risk of re-infection, poor adherence and low
success rate.
Methods: A retrospective data review of 159 inmates, positive for anti-Hepatitis C virus (HCV) antibody, evaluated
to National Institute for Infectious Diseases “L. Spallanzani” (INMI) from January 2006 to December 2009, was
conducted to evaluate rate of completion (feasibility) and outcome efficacy of chronic Hepatitis C Virus (HCV)
infection treatment with Pegylated Interferon and Ribavirin in five correctional facilities in Rome.
Results: Of the 159 inmates evaluated in the study period, 50, all male (median age 39 years) were treated. Twenty
patients (40%) did not complete treatment: 15 showed no response and therapy was stopped, 5 patients (10%)
interrupted treatment because of adverse reactions. The global feasibility was 60%. The overall sustained virologic
response (SVR) was 50% (32% for genotype 1 and 68% for genotype other than 1). The main predictors of SVR at
the Multivariable Logistic Regression Odds Ratio (MLR-OR) were a better pretreatment histological diagnosis
(absence of bridging fibrosis or cirrhosis [MLR-OR 11.85; 95% CI 1.96-71.62) and a HCV genotype other than 1
(MLR-OR 5.87; 95% CI 1.49-23.17).
Conclusions: Chronic HCV infection treatment in correctional facilities is feasible and effective and should be
strongly recommended, in combination with preventive measures, in appropriately screened patients because it
represents an important opportunity to treat a population with a high prevalence of chronic HCV infection among
whom treatment options post incarceration may be limited.
Keywords: Hepatitis C, Correctional facility, Inmates, Sustained response
Background
In Italy the estimated prevalence of anti-Hepatitis C virus
(HCV) antibody seropositivity in the general population is
2,9%,with a north–south gradient and increasing with age
[1,2]. Rates are considerably higher in the Italian correc-
tional population (38%) because of the higher proportion
of intravenous drug users (IVDUs) [3].
Despite the relatively high success rates reported in
the U.S. and Canada correctional population [4-9], sev-
eral factors reported as potential obstacles to treatment
of chronic HCV infection in the general population,
such as active drug substance abuse, psychiatric illness,
length of treatment, risk of re-infection, poor adherence
and low success rates, may be more prevalent in this
setting [5,8,10].
Many accurate data are published on the prevalence of
HCV infection in the correctional population in Europe
[2,11,12], but in the same population few data are avail-
able on the outcome of treatment of chronic HCV
infection [12,13].
To evaluate feasibility and efficacy of treatment of
chronic HCV infection in this setting, a retrospective re-
view of medical records was performed in a cohort of in-
mates in five correctional facilities in Rome.
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Were retrospectively evaluated data of 159 inmates (148
males, 11 females) who tested positive for anti-HCV anti-
body (HCV-Ab) at their entry in five correctional facilities
in Rome (Casa Circondariale(CC) Regina Coeli, and
Istituti Penitenziari Rebibbia, which include: CC Nuovo
Complesso, CC Femminile, Casa di Reclusione, III Casa,
Casa di Reclusione; average daily census 2541 in the study
period) and were sent for consultation at the National In-
stitute for Infectious Diseases “L. Spallanzani” (INMI),
Rome, from January 2006 to December 2009.
All inmates were tested for HCV-Ab, HCV viremia
(HCV-RNA), human immudeficiency virus antibodies
(HIV-Ab) and hepatitis B surface antigen (HBsAg). Sero-
logic tests were performed using microparticle enzyme
immunoassays (EIAs) for HBsAg (AxSYM, Abbott,
Wiesbaden, Germany), HCV 3.0 third-generation EIAs
(Abbott) for HCV-Ab and the Genscreen HIV 1/2
ELISA (BioRad, Marnes La Coquette, France) for HIV-Ab.
HCV-RNA was measured using the COBAS Taq-Man
HCV test (Roche Molecular System) with a detection limit
of 12 IU/ml. If patients had HCV-RNA detectable in
serum, HCV genotype was determined using the reverse
hybridization method (InnoLipa HCV II; Siemens Medical
Solutions Diagnostics, Tarrytown, NY), those with an
expected length of stay in the correctional facility of less
than 12 (for genotypes 2, 3) or 18 (for genotypes 1, 4)
months necessary for evaluation, uninterrupted treat-
ment and follow-up were not considered eligible for
treatment. The remaining population underwent clin-
ical and laboratory evaluation to assess contraindica-
tions to treatment with interferon and ribavirin, including
psychiatric consultation and screening for drugs or alco-
hol abuse: patients were considered eligible for immediate
treatment if they were on rehabilitation or stable main-
tenance agonist therapy (methadone) according recom-
mendations of Italian Association for the Study of the
Liver (A.I.S.F.), Italian Society of Infectious and Tropi-
cal Diseases (S.I.M.I.T.), Italian Federation Department’s
Operators and Addiction Services (FederSerD), Italian
Prison Medicine and Healthcare Society (S.I.M.S.Pe)
[14,15].
For the many inmates who were in the process of being
transferred to other correctional facilities depending for
health assistance from other institutions outside Rome, or
were going to be released and living outside our area, initi-
ation of treatment was deferred and they were referred for
treatment and clinical and virological follow-up to other
healthcare facilities in the place of final residence.
Information on length of incarceration was available
on clinical charts only as categorical variable: for geno-
types 1 and 4 < or > of 18 months; for the other geno-
types < or> of 12 months.
Figure 1 shows the decisional algorithm for eligibility
to treatment.
Patients were offered treatment if they had undergone
a liver biopsy at INMI that was consistent with chronic
hepatitis and had been categorized as F1 to F4 according
to METAVIR system for fibrosis staging [16].
Standard guidelines for treatment of chronic HCV in-
fection, available at the time of patient’s evaluation, were
followed [17]. Genotypes 1 and 4 were treated for 48
weeks with Pegylated Interferon-α2a, 180 μcg subcuta-
neously once a week, in combination with Ribavirin 15
mg/kg/day. Genotypes 2 and 3 were treated for 24 weeks
with Pegylated Interferon-α2a, 180 μg subcutaneously
once a week in combination with Ribavirin 800 mg/day.
Pegylated Interferon-α2a was administered by directly ob-
served therapy (DOT) while Ribavirin was self administered.
Side effects were regularly monitored and therapy was
modified or stopped according to standard guidelines.
In accordance with provisions of the regulatory au-
thority “Agenzia Italiana del Farmaco” (A.I.F.A.) in force
at 2008, when we had conducted this study, the approval
of the Ethics Committee was not required for retrospect-
ive observational studies [18].
Data analysis
The measure of feasibility was the rate of treatment comple-
tion. The measure of efficacy was the rate of sustained viro-
logic response (SVR), defined as undetectable HCV-RNA in
serum at the end of follow-up, 24 weeks after treatment
withdrawal. The whole treated population - i.e. all patients
who received at least one dose of study medication- was in-
cluded in the analysis (intention to treat analysis).
Association between SVR and selected patients’ char-
acteristics was assessed by means of Odds Ratios (ORs)
and their 95% Confidence Intervals (95% CI) in order to
define predictors of SVR in the study population using
Logistic Regression.
χ2 test (or Fisher’s exact test when applicable) or Mann
Whitney non-parametric test were used to compare groups
for categorical or continuous variables, respectively.
Univariable analysis was conducted to select significant
variables (p<0.10) to be included in the multivariable ana-
lysis, in which Multivariable Logistic Regression Odds ra-
tio (MLR-OR) was calculated. Were considered two
different models: Model I in which all selected variables
were included, and Model II in which the final model in-
cluded only those variables selected after a backward elim-
ination (p<0.10) of those variables included in Model I.
Statistical analysis was performed using SPSS ver. 19
(SPSS Inc).
Results and discussion
Fifty-nine out of 159 (37%) inmates evaluated in the
study period were considered eligible for treatment; only
Iacomi et al. BMC Infectious Diseases 2013, 13:374 Page 2 of 7
http://www.biomedcentral.com/1471-2334/13/374
nine declined therapy while 50 patients started treat-
ment. No difference in the baseline characteristics was
found between treated subjects and those who refused
therapy. The overall HCV treatment rate was 31.4% (50/
159), while 100 patients were considered ineligible for
treatment and nine declined therapy. No difference in
the baseline characteristics was found between treated
subjects and those who refused therapy.
Among 100 patients considered ineligible, the most
frequent reason (69%) for not-treatment was length of
detention. As explained in methods section, we could
not calculate the median length of incarceration of these
patients, but this information was available for overall
inmates in the five correctional facilities (source: “De-
partment of Penitentiary Administration - Ministry of
Justice”). The overall average length of incarceration in
the five correctional facilities during the study was 9.5
months . In 26 patients treatment was contraindicated for
psychiatric problems (14 patients) or for substance abuse
(12 patients). For the remaining 5% treatment was not in-
dicated due to absence of HCV replication (4 patients) or
decompensated cirrhosis (1 patient).
All 50 treated patients underwent liver biopsy. Among
them 34 (68%) had a substance abuse history and 47
(94%) were naïve for interferon and ribavirin.
Baseline characteristics of eligible patients are summa-
rized in Table 1.
Thirty patients (60%), 11 with genotype 1, one with
genotype 4, 17 with genotype 3 (one co-infected with
HIV) and one with genotype 2, showed an end of treat-
ment response: 25 (83%) achieved a SVR, including the
HIV co-infected patient, while 5 (17%) relapsed. The glo-
bal SVR rate was 50%. SVR according to genotype was
32% (8/25) for genotype 1, 50% (1/2) for genotype 4 and
70% (16/23) for genotypes 2–3.
Twenty patients did not complete treatment: 15
showed no response (9 null and 6 non responder) and
therapy was therefore stopped, including two HIV co-
infected patients with genotype 1, while 5 patients
interrupted treatment because of adverse reactions (two
cases of severe thrombocytopenia, and one each of inter-
stitial pneumonia, severe rash and depression).
Univariable regression analysis showed that younger age
(<40 years, OR=3.27, p=0.048), better pretreatment histo-
logical diagnosis (F1-F2 vs. F3-F4, OR=9.04, p=0.009),
HCV genotype other than 1 (OR=4.52, p=0.013) and lower
baseline viral load (<6×105 UI/mL, OR=2.92, p=0.082)
were predictive of SVR (Table 2).
Multivariable logistic regression analysis after back-
ward elimination procedure, shown in Table 3, con-
firmed that better pretreatment histological diagnosis
(absence of bridging fibrosis or cirrhosis) and a HCV ge-
notypes other than 1 were best predictive of SVR.
Few data are available on the outcome of treatment of
chronic HCV infection in the correctional population in
Italy with no study in patients who all undergone to liver
biopsy.
The rate of treatment completion (60%), the proportion
of patients that interrupted treatment because of adverse
events (10%), the overall rate of SVR (50%) and genotype-
specific rates of SVR (32% for genotype 1, and 68% for ge-
notypes other than 1), were substantially similar to those
reported in previous and recent studies among American
inmates [3-6], and in the community [19-21]. Genotypes
other than 1 and absence of bridging fibrosis or cirrhosis
were independently associated with SVR, a finding well
established in the literature [19,20,22].
Factors reported as potential obstacles to treatment of
chronic HCV infection, especially in correctional popu-
lations [5,8,10], such as active drug substance abuse, psy-
chiatric illness, length of treatment and poor adherence
did not affect the end points of this study.
Feasibility and efficacy of treatment among patients with
a previous history of IVDU did not differ significantly
Figure 1 Algorithm for evaluation of patients eligible to the treatment.
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from those of patients without an history of IVDU (61%
and 47.1% vs 58% and 56.3%, respectively); treatment
withdrawal rate caused by psychiatric illness was very low
(2%), and finally, because patients were considered eligible
for treatment if they had an expected length of stay of at
least 12 or18 months in the facility, adequate treatment
and follow-up duration were ensured by INMI and no pa-
tient was lost to follow-up.
Despite advances in treatment and remarkable im-
provements in cure rates, few persons with chronic
HCV infection are receiving treatment in some settings.
Studies in various correctional facilities have suggested
that 59 to 85% of patients presenting with confirmed
HCV infection go untreated; [8,10,12,13]. Recently Rice
has reported a lower proportion (40%) of untreated pa-
tients [9].
In general populations this proportion varies from 73%
to 91% [23-26]. In our study population the 68.6% of pa-
tients did not receive HCV treatment, consistent with
that reported among patients referred to correctional
facilities.
The most frequent reason (69%) for non-treatment was
the length of detection. Spaulding reports that only a small
proportion of inmates are treated: those with an expected
remaining stay in prison at least 18 to 24 mounths [27].
We believe that the minimum duration of detention, ne-
cessary for uninterrupted treatment and follow-up for pa-
tients eligible for an immediate treatment must be at least
12 months for genotypes 2 and 3, and 18 months for ge-
notypes 1 and 4. This issue highlights the importance of
postdischarge planning, adequate community resources,
and continuity of care for inmates, in whom the potential
exists for successful treatment outcomes, in order to in-
crease the access to treatment.Continuity of care for
prison inmates with chronic HCV infection is ensured by
INMI through outpatients’ service.
Chronic HCV infection can lead to cirrhosis and liver
cancer and contributes to morbidity and mortality.
Given the high prevalence of chronic HCV infection in
the correctional facilities, it is important to identify and
evaluate inmates for treatment.
The average length of incarceration in the five correc-
tional facilities is 9.5 months, and most incarcerated indi-
viduals return to their communities. Therefore, treatment
of chronically infected individuals in the correctional set-
ting may be an effective strategy to reduce the incidence
and prevalence of viral hepatitis in the community. Indeed,
prisons could serve as a reservoir, resulting in the amplifi-
cation of HCV and other infectious disease transmission in
the community after the release of infected inmates or of
those who became infected while incarcerated [28].
In the future new therapies with direct-acting antivirals
(DAAs) and evolving standard of care will challenge the
exclusion based on length incarceration. Moreover in this
population use of new DAAs, currently available, and those
available in the future, might markedly improved SVR rates
in the treatment of chronic HCV infection [29-32].
Despite the promising scenario of future therapies,
HCV infected inmates will remain for many years a hard
to reach and hard to treat population. Therefore, public
health and correctional institutions should collaborate to
develop prevention programs including immunization,
health education and substance abuse treatment for in-
mates. It is worrisome that not all prisoners undergo
screening for these infections. Data from a sample of in-
mates evaluated for bloodborne infections in 2009–2010
demonstrate that 11.7% of inmates were screened for
Table 1 Baseline characteristics of 50 inmates treated for
chronic HCV infection at national institute for infectious
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HIV, while HCV and HBV testing percentage was lower
[33]. The study has some limitations which may impact
our findings. Being a retrospective study, a significant
sampling selection bias might have occurred, as anti-
HCV screening of inmates does not cover the entire cor-
rectional populations. Moreover since we have evaluated
only inmates for which the correctional physician re-
quested a specialist consultation at our Institute, a popu-
lation of patients more suitable to treatment could have
been selected. Moreover, all treated subjects were males,
which limits the generalizability of the results to the fe-
male inmate population.
Conclusions
In this study treatment of chronic HCV infection in cor-
rectional facilities was feasible and safe with good
chances to achieve SVR. Also in this population use of
new DAAs currently available, and those available in the
future, might markedly improved SVR rates in the treat-
ment of chronic HCV infection.
Treatment of chronic HCV infection in correctional fa-
cilities should be strongly recommended, in combination
with preventive measures, in appropriately screened pa-
tients because it represents an important opportunity to
Table 2 Univariate analysis of the association of SVR with patients characteristics
SVR No SVR Tot OR 95% CI p
N % N %
Age (years)
40+ 7 33.3 14 66.7 21 1
<40 18 62.1 11 37.9 29 3.27 1.01-10.62 0.048
BMI (kg/m2)
<25 10 41.7 14 58.3 24 1
25+ 15 57.7 11 42.3 26 1.91 0.62-5.88 0.260
IVDUs
Yes 16 47.1 18 52.9 34 1
No 9 56.3 7 43.8 16 1.45 0.44-4.78 0.545
Biopsy staging (Metavir)
F3-F4 2 15.4 11 84.6 13 1
F1-F2 23 62.6 14 37.8 37 9.04 1.74-46.89 0.009
ALT (mU/mL)
60+ 18 45.0 22 55.0 40 1
<60 7 70.0 3 30.0 10 2.85 0.-64-12.64 0.168
HCV genotype
1 8 32.0 17 68.0 25 1
Not 1 17 68.0 8 32.0 25 4.52 1.38-14.82 0.013
aHCV viral load (IU/ml)
High 13 40.6 19 59.4 32 1
Low 12 66.7 6 33.3 18 2.92 0.87-9.78 0.082
acategorized in High (≥6×105 IU/ml) and Low (<6×105 IU/ml).
BMI Body Mass Index, IVDUs Intravenous drug users, SVR Sustained Virologic Response, OR Odds Ratio, CI Confidence Interval.
Table 3 Multivariate analysis of the association of SVR
with selected patients characteristics
Model I Model II






F1-F2 9.29 1.47-58.64 11.85 1.96-71.62
HCV genotype
1 1 1
Not 1 5.19 1.27-21.18 5.87 1.49-23.17
aHCV viral load (IU/ml)
High 1
Low 1.61 0.38-6.91
Model I: Including all variables found to be significant (p<0.10) at
univariate level.
Model II: Final model obtained through backward elimination starting from all
variables included in Model I.
acategorized in Low (<6×105 IU/ml) and High (≥6×105 IU/ml).
SVR Sustained Virologic Response, MLR-OR Multivariable Logistic Regression
Odds Ratio, CI Confidence Interval.
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treat a population with a high prevalence of chronic HCV
infection among whom treatment options post incarcer-
ation may be limited.
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